Abstract:BACKGROUND AND PURPOSEEmodin [1,3,8-trihydroxy-6-methylanthraquinone] has been reported to exhibit vascular anti-inflammatory properties. However, the corresponding mechanisms are not well understood. The present study was designed to explore the molecular target(s) of emodin in modifying lipopolysaccharide (LPS)-associated signal transduction pathways in endothelial cells.EXPERIMENTAL APPROACHCultured primary human umbilical vein endothelial cells (HUVECs; passages 3-5) were pre-incubated with emodin (1-50 mg.mL(-1)). LPS-induced expression of pro-inflammatory cytokines [interleukin (IL)-1 beta, IL-6] and chemokines (IL-8; CCL2/MCP-1) were determined by reverse transcription-PCR and ELISA. Nuclear factor-kappa B (NF-kappa B) activation, inhibitor of kappa B (I kappa B) a degradation and Toll-like receptor-4 (TLR-4) were detected by immunocytochemistry and Western blotting. Cholesterol depletion [by methyl beta-cyclodextrin (MBCD), a specific cholesterol binding agent] and cholesterol replenishment were further used to investigate the roles of lipid rafts in activation of HUVECs.KEY RESULTSEmodin inhibited, concentration-dependently, the expression of LPS-induced pro-inflammatory cytokines (IL-1 beta, IL-6) and chemokines (IL-8, CCL2) and, in parallel, inhibited NF-kappa B activation and I kappa B alpha degradation in HUVECs. However, emodin did not inhibit the NF-kappa B activation and I kappa B alpha degradation induced by IL-1 beta. The cholesterol binding agent, MBCD, inhibited LPS-induced NF-kappa B activation in passaged HUVECs [which also lack the LPS receptor, membrane CD14 (mCD14)], showing that lipid rafts played a key role in LPS signalling in mCD14-negative HUVECs. Moreover, emodin disrupted the formation of lipid rafts in cell membranes by depleting cholesterol.CONCLUSIONS AND IMPLICATIONSLipid rafts were crucial in facilitating inflammatory responses of mCD14-negative HUVECs to LPS. Emodin disrupted lipid rafts through depleting cholesterol and, consequently, inhibited inflammatory responses in endothelial cells.

Emodin Attenuates Lipopolysaccharide-Induced Acute Liver Injury via Inhibiting the TLR4 Signaling Pathway in vitro and in vivo .

Emodin Protects Against Lipopolysaccharide-Induced Acute Lung Injury via the JNK/Nur77/c-Jun Signaling Pathway

Emodin Protects Against Lipopolysaccharide-Induced Acute Lung Injury <i>via</i> the JNK/Nur77/c-Jun Signaling Pathway

Emodin Ameliorated Lipopolysaccharide-Induced Fulminant Hepatic Failure by Blockade of TLR4/MD2 Complex Expression in D-galactosamine-sensitized Mice.

Emodin Ameliorates LPS-induced Acute Lung Injury, Involving the Inactivation of NF-κB in Mice.

Emodin reactivated autophagy and alleviated inflammatory lung injury in mice with lethal endotoxemia

Emodin alleviated pulmonary inflammation in rats with LPS-induced acute lung injury through inhibiting the mTOR/HIF-1α/VEGF signaling pathway

Emodin Inhibits LPS-induced Inflammatory Response by Activating PPAR-γ in Mouse Mammary Epithelial Cells.

Liver Protective And Reactive Oxygen Species Scavenging Effects Of Emodin In Lipopolysaccharide/Bacillus Calmette Guerin-Injured Mice By Optical Molecular Imaging

Emodin Alleviates Liver Fibrosis of Mice by Reducing Infiltration of Gr1(hi) Monocytes

Exploration of Emodin to Treat Alpha-Naphthylisothiocyanate-induced Cholestatic Hepatitis Via Anti-Inflammatory Pathway.

Emodin Protects Sepsis Associated Damage to the Intestinal Mucosal Barrier Through the VDR/ Nrf2 /HO-1 Pathway

Emodin Ameliorates Acute Pancreatitis-Associated Lung Injury Through Inhibiting the Alveolar Macrophages Pyroptosis

Emodin Attenuates Acetaminophen-Induced Hepatotoxicity via Cgas-STING Pathway

Emodin Protects Against Concanavalin A-induced Hepatitis in Mice Through Inhibiting Activation of the P38 MAPK-NF-κB Signaling Pathway.

Emodin Suppresses Lipopolysaccharide-Induced Pro-Inflammatory Responses And Nf-Kappa B Activation By Disrupting Lipid Rafts In Cd14-Negative Endothelial Cells

Emodin ameliorates lipopolysaccharide-induced mastitis in mice by inhibiting activation of NF-κB and MAPKs signal pathways.

Emodin Improves Lipopolysaccharide‐Induced Microcirculatory Disturbance in Rat Mesentery

Emodin Blocks mPTP Opening and Improves LPS‐induced HMEC‐1Cell Injury by Upregulation of ATP5A1

Emodin: an alveolar macrophage protector in acute pancreatitis induced lung injury

Protective Effects of Emodin on Lung Injuries in Rat Models of Liver Fibrosis